Associations between Measured and Patient-Reported Physical Function and Survival in Advanced NSCLC
Authors:
- Kristin StokkeKSKristin Stokke
- Tarje Onsøien HalvorsenTHTarje Onsøien Halvorsen
- Bjørn Henning GrønbergBGBjørn Henning Grønberg
- Ingvild SaltvedtISIngvild Saltvedt
- Marit SlaaenMSMarit Slaaen
- Øyvind KirkevoldØKØyvind Kirkevold
- Kristin Toftaker KillingbergKKKristin Toftaker Killingberg
- Marie Søfteland SandveiMSMarie Søfteland Sandvei
Open Access
- 17 May 2022
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 10 (5) , 922
Abstract
Background: There is a lack of tools for selecting patients with advanced lung cancer who benefit the most from systemic treatment. Patient-reported physical function (PRPF) has been identified as a prognostic factor in this setting, but little is known about the prognostic value in advanced non-small-cell lung cancer (NSCLC). The aim of this study was to investigate if measured physical performance was an independent or stronger prognostic factor than PRPF in patients with advanced NSCLC receiving platinum-doublet chemotherapy. Methods: We analyzed patients from a randomized trial comparing immediate and delayed pemetrexed therapy in stage III/IV NSCLC (n = 232) who performed timed up and go (TUG) and 5 m walk test (5 mWT) and reported physical function on the EORTC QLQ-C30 before chemotherapy commenced. Results: Overall, 208 patients performed TUG and 5 mWT and were included in the present study. Poor physical function was significantly associated with poor survival (TUG: HR 1.05, p < 0.01, 5 mWT: HR 1.05, p = 0.03, PRPF: 1.01, p < 0.01), but only PRPF remained an independent prognostic factor in multivariable analyses adjusting for baseline characteristics (HR 1.01, p = 0.03). Conclusions: Patient-reported, but not measured, physical performance was an independent prognostic factor for survival in patients with advanced NSCLC receiving platinum-doublet chemotherapy.Keywords
Funding Information
- The Research Council of Norway
- Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU)
This publication has 25 references indexed in Scilit:
- Normative Values of Cognitive and Physical Function in Older Adults: Findings from The Irish Longitudinal Study on AgeingJournal of the American Geriatrics Society, 2013
- Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for CancerJournal of Clinical Oncology, 2012
- Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot studyCritical Reviews in Oncology/Hematology, 2011
- Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin–gemcitabine or carboplatin–paclitaxel: NVALT-3 a phase III studyAnnals of Oncology, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6Journal of Thoracic Oncology, 2007
- Reference Values for the Timed Up and Go TestJournal of Geriatric Physical Therapy, 2006
- Prognostic Value of Usual Gait Speed in Well‐Functioning Older People—Results from the Health, Aging and Body Composition StudyJournal of the American Geriatrics Society, 2005
- Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials GroupEuropean Journal of Cancer, 2005
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993